secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2026-05-14T20:06:05+00:00
Accession:  0001104659-26-061148
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia Q1 net loss $3.8M; Phase 1 Part 3 dosing started for DA-1726
--------------------------------------------------------------------

- Net loss of $3.8M ($0.79 per share) vs $3.7M ($3.93 per share) in Q1 2025.
- Cash and cash equivalents $13.7M as of March 31, 2026, sufficient into Q4 2026.
- First patient dosed in Phase 1 Part 3 16-week titration study of DA-1726; data expected Q4 2026.
- January 2026 public offering raised ~$9.3M gross proceeds to fund operations.
- R&D expenses $2.1M, G&A $1.9M; total operating expenses $4.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926061148/0001104659-26-061148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926061148/mtva-20260514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-061148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer